Our Portfolio

Below companies have either been created by Forty51 Ventures or received their first financing from Forty51 Ventures as lead, or co-lead investor, in its first institutional financing.

Mosanna Therapeutics, Basel

2022

Metabolic Obstructive Sleep Apnea

Neuroluna Therapeutics AG, Basel

2023

Neurodegenerative Diseases Associated with Immune Dysfunction

Mysthera Therapeutics AG

2023

Chronic autoimmune Diseases Associated with Multicellular Pathology and Tertiary Lymphoid Structures

Allegria Therapeutics, Basel

2023

Acute and Chronic Mast-Cell Driven Diseases

Melodia Therapeutics, Basel

2023

Neutrophil-Driven Diseases

Cartilla Therapeutics, Basel

2024

Company in Stealth Mode